In this video, Austin Smith interviews Jim Mueller, author of the Fool's premium report on Express Scripts. Jim thinks the company is a buy for three reasons:
- $290 billion of drugs are coming off-patent over the next five years, and the company can benefit from selling more profitable generics.
- The U.S. and European populations are aging.
- Obamacare will bring many more people onto the rolls.
For more details, check out the video.
Do lower costs = profits for your portfolio?
In 2011, a massive shift began. With the first of the baby boomer generation reaching Medicare age, America's health-care landscape was forever changed. Combine the aging population with the impact of Obamacare, and the need for innovative solutions for skyrocketing health-care costs is as clear as ever. Express Scripts is part of that solution, and in this brand-new premium report on the company, we clearly lay out the opportunity in front of this misunderstood stock. Claim your copy by clicking here now.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.